A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death.

Details

Ressource 1Download: 34940522_BIB_CD2857AF9E9B.pdf (775.26 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_CD2857AF9E9B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death.
Journal
Journal of cardiovascular development and disease
Author(s)
Gutiérrez-Abejón E., Herrera-Gómez F., Martín-García D., Tamayo E., Álvarez F.J.
ISSN
2308-3425 (Electronic)
ISSN-L
2308-3425
Publication state
Published
Issued date
29/11/2021
Peer-reviewed
Oui
Volume
8
Number
12
Pages
167
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
A high percentage of patients with COVID-19 (coronavirus disease 2019) have previous cardiovascular disease (CVD). The findings presented here came from an epidemiological population-based registry study (real-world data) that enrolled all in-hospital COVID-19 patients with previous CVD from 1 March to 31 May 2020. Death, other comorbidities, hospital stay variables, ventilation type, and main clinical outcomes were evaluated. In Castile and Leon, 35.83% of the 7307 in-hospital COVID-19 patients who participated in this study had previous CVD, particularly arrhythmias (48.97%), cerebrovascular disease (25.02%), ischemic heart disease (22.8%), and chronic heart failure (20.82%). Of the patients, 21.36% were men and more than 90% were over 65 years of age, and the mortality rate achieved 32.93%. The most used medicines were antibiotics (91.41%), antimalarials (73.3%), steroids (46.64%), and antivirals (43.16%). The main predictors of death were age over 65 years (OR: 5), ventilation needs (OR: 2.81), treatment with anti-SIRS (systemic inflammatory response syndrome) medicines (OR: 1.97), antivirals (OR: 1.74) or steroids (OR: 1.68), SIRS (OR: 5.75), SARS (severe acute respiratory syndrome) (OR: 2.44), or AKI (acute kidney injury) (OR: 1.63) occurrence. Chronic heart failure and cerebrovascular disease were associated with a worse clinical course of COVID-19, especially in men older than 65 years with diabetes who developed SIRS, SARS, or AKI.
Keywords
COVID-19, SARS-CoV-2, cardiovascular diseases, cerebrovascular diseases, clinical characteristics, heart failure, mortality, treatment
Pubmed
Web of science
Open Access
Yes
Create date
04/01/2022 10:07
Last modification date
08/08/2024 7:40
Usage data